Cidara’s Rezafungin Hits Approvable Endpoints For Candida Infections

 
• By Joseph Haas

Phase III data for the novel echinocandin demonstrated non-inferiority to caspofungin for all-cause mortality at day 30 and for global cure at day 14. Regulatory filings are planned for 2022.

IV solution in a child's patients hand
Cidara hopes its weekly I.V. antifungal will improve therapy for Candida infections

More from Clinical Trials

More from R&D